Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis: Learning From Adversity

JAMA Neurol. 2017 Aug 1;74(8):907-908. doi: 10.1001/jamaneurol.2017.0325.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alemtuzumab*
  • Autoimmune Diseases
  • Humans
  • Lymphocytes
  • Multiple Sclerosis*
  • Multiple Sclerosis, Relapsing-Remitting

Substances

  • Alemtuzumab